1-2 of 2
Daniel Vorobiof
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Christian Taverna, MD, Giovanni Martinelli, MD, Felicitas Hitz, MD, Walter Mingrone, MD, Thomas Pabst, MD PhD, Lidija Cevreska, MD PhD, Auro del Giglio, MD, Anna Vanazzi, MD, Daniele Laszlo, MD, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, MD, Emanuele Zucca, Celine Rueegsegger, Stephanie - Rondeau, Corinne Rusterholz, Michele Ghielmini
Journal: Blood
Blood (2018) 132 (Supplement 1): 1601.
https://doi.org/10.1182/blood-2018-99-116864
Published: 2018
Journal Articles

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule

Clinical Trials & Observations
Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio B. Cogliatti, Gabriella Pichert, Jörg Hummerjohann, Ursula Waltzer, Martin F. Fey, Daniel C. Betticher, Giovanni Martinelli, Fedro Peccatori, Urs Hess, Emanuele Zucca, Roger Stupp, Tibor Kovacsovics, Claudine Helg, Andreas Lohri, Mario Bargetzi, Daniel Vorobiof, Thomas Cerny, for the Swiss Group for Clinical Cancer Research (SAKK)
Journal: Blood
Blood (2004) 103 (12): 4416–4423.
https://doi.org/10.1182/blood-2003-10-3411
Published: 2004